ANKİLOZAN SPONDİLİT HASTALARINDA İRRİTABL BARSAK SENDROMU SIKLIĞI

Yıl 2020, , 117 - 123, 23.08.2020

Okan Avcı , Rafet Mete , Dilek Solmaz

https://doi.org/10.37696/nkmj.678114

Öz

ÖZ
SUMMARY
THE PREVALENCE OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Objective:

Irritable bowel syndrome (IBS) is a functional bowel disease, characterized by altered bowel habits and chronic abdominal pain. IBS has an increased association with inflammatory pathologies such as rheumatoid arthritis (RA), but the role of inflammation in the pathophysiology of IBS hasn’t been clarified yet. Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton. The aim of our study is to determine the frequency of IBS in AS, and to reveal its relationship with other factors, primarily with disease activity.

Material and Method:

145 patients with AS in the rheumatology clinic of Namık Kemal University were included. Along with demographic, clinical and laboratory data of the patients, disease activity and biologic drug use were recorded. The diagnosis and type of IBS were examined according to ROME III criteria.


Results:

The prevalence of IBS in patients with AS was 31.7%. Frequency of IBS was significantly higher in higher disease activity group (BASDAI>4) and in patients treated with biological agents (p values <0.001, 0.010, respectively). IBS was significantly higher in female patients by gender and young patients (<50) by age (p: 0.012 and p: 0.01 respectively).

Conclusion:

IBS, when compared to the normal population, was found to be higher (%31,7) in patients with AS. The relationship between AS disease activity score and IBS suggests the effect of inflammation in pathogenesis.
As a result, in patients with AS, especially with high disease activity, gastroenterological complaints should be questioned; and IBS as frequent comorbidity, shouldn’t be ignored in the follow-up.

ÖZET
ANKİLOZAN SPONDİLİT HASTALARINDA İRRİTABL BARSAK SENDROMU SIKLIĞI
Amaç:
İrritabl barsak sendromu (İBS), barsak alışkanlıklarında değişim ve kronik karın ağrısı ile karakterize bağırsağın fonksiyonel bir hastalığıdır. İBS’ nin Romatoid artrit (RA) gibi inflamatuar patolojilerle artmış birlikteliğine rağmen, patofizyolojisinde inflamasyonun rolü netleştirilebilmiş değildir. Ankilozan Spondilit (AS) başlıca aksiyel iskelet sistemini tutan, kronik inflamatuvar bir hastalıkdır. Çalışmamızın amacı AS’ de İBS sıklığını tespit etmek ve bunun başta hastalık aktivitesi olmak üzere diğer faktörlerle ilişkisini ortaya koymaktır.

Materyal ve Metod:

Çalışmaya Namık Kemal Üniversitesi romatoloji kliniğindeki 145 AS tanılı hasta dahil edildi. Hastaların demografik, klinik ve laboratuvar verileri ile birlikte hastalık aktivitesi ve biyolojik ilaç kullanımı kaydedildi. ROMA III kriterlerine göre İBS tanısı ve tipi incelendi.

Bulgular:

AS hastalarındaki İBS sıklığı %31.7 idi. İBS sıklığı hastalık aktivitesi yüksek olan (BASDAI>4) ve biyolojik ajan tedavisi alanlarda anlamlı şekilde yüksekti (p<0.001 ve p: 0.01 sırasıyla). Cinsiyetler arasında İBS kadın hastalarda, yaşa göre ise genç hastalarda (<50 yaş) anlamlı şekilde yüksekti (p: 0.012 ve p<0.01 sırasıyla).

Sonuç:

İBS; AS hastalarında normal popülasyona kıyasla daha yüksek (%31.7) tespit edildi. AS hastalık aktivite skoru ile İBS arasındaki ilişki patogenezde inflamasyonun etkisini düşündürdü. Sonuç olarak özellikle hastalık aktivitesi yüksek olan AS hastalarında gastroenterolojik şikayetler sorgulanmalı, sık bir komorbidite olan İBS takip sürecinde göz ardı edilmemelidir.

Anahtar Kelimeler

İrritabl barsak sendromu, ankilozan spondilit, inflamasyon

Kaynakça

• 1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643-50.
• 2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21 e4.
• 3. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000.
• 4. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58.
• 5. Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol. 2005;19(4):231-4.
• 6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
• 7. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107(12):1793-801; quiz 802.
• 8. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27(1):37-40.
• 9. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology. 1994;106(4):945-50.
• 10. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122(7):1778-83.
• 11. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(2):404-10.
• 12. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123(6):1972-9.
• 13. Garcia Carrasco M, Mendoza Pinto C, Lopez Colombo A, Mendez Martinez S, Andari Sawaya R, Munoz Guarneros M, et al. Irritable bowel syndrome-type symptoms in female patients with mild systemic lupus erythematosus: frequency, related factors and quality of life. Neurogastroenterol Motil. 2013;25(12):958-66.
• 14. Myasoedova E, Talley NJ, Manek NJ, Crowson CS. Prevalence and risk factors of gastrointestinal disorders in patients with rheumatoid arthritis: results from a population-based survey in olmsted county, Minnesota. Gastroenterol Res Pract. 2011;2011:745829.
• 15. Almodovar R, Carmona L, Zarco P, Collantes E, Gonzalez C, Mulero J, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28(6 Suppl 63):S33-9.
• 16. Wallman JK, Mogard E, Marsal J, Andreasson K, Joud A, Geijer M, et al. Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity? Ann Rheum Dis. 2019.
• 17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8.
• 18. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21(9):1694-8.
• 19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
• 20. American College of Gastroenterology Task Force on Irritable Bowel S, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-35.
• 21. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-80.
• 22. Hahn BA, Saunders WB, Maier WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci. 1997;42(12):2585-90.
• 23. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ, 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927-34.
• 24. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47(1):225-35.
• 25. Özden A. İrritabl Barsak Sendromu: Türk Gastroenteroloji Vakfı; 2006.
• 26. Karaman N, Turkay C, Yonem O. Irritable bowel syndrome prevalence in city center of Sivas. Turk J Gastroenterol. 2003;14(2):128-31.
• 27. Özden A. Türkiye’de birinci basamak sağlık kurumlarında irritabl barsak sendromu görülme sıklığı. Akademik Gastroenteroloji Dergisi. 2006:4-15.
• 28. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94(12):3541-6.
• 29. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693-702.
• 30. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203-9.
• 31. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol.107(10):1474-82.
• 32. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(10):1474-82.
• 33. Sundstrom B, Wallberg-Jonsson S, Johansson G. Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis. Clin Rheumatol. 2011;30(1):71-6.